GEN-1: Clinical Trials

4 trials of GEN-1, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 completed, 1 terminated. 4 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 14Completed 3, Terminated 1

Follow GEN-1: new trials by email Literature Review of GEN-1 trials Research Report on GEN-1

Trials (filtered) newest first · largest first

All 4 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study of Safety & Biological Activity of IP IMNN-001 (also Known As GEN-1) with Neoadjuvant Chemo in Ovarian Cancer
IMNN-001 - Epithelial Ovarian Cancer, Fallopian Tube Cancer
Phase 1CompletedImunon182015-09-012024-10-02
EGEN-001 and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Laboratory Biomarker Analysis, PEG-PEI-cholesterol Lipopolymer-encased IL-12 DNA Plasmid Vector GEN-1, Pegylated Liposomal Doxorubicin Hydrochloride - Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma
Phase 1CompletedGynecologic Oncology Group162012-07-092019-03-12
Safety and Efficacy of EGEN-001 Combined With Carboplatin and Docetaxel in Recurrent, Platinum-Sensitive, Ovarian Cancer
EGEN-001 (phIL-12-005/PPC) - Ovarian Neoplasms
Phase 1CompletedEGEN, Inc.132007-04-012013-03-26
Safety Study of phIL-12-005/PPC to Treat Recurrent Ovarian Cancer
EGEN-001 (phIL-12-005/PPC) - Ovarian Neoplasms
Phase 1TerminatedEGEN, Inc.182005-08-012013-02-28

Conditions studied

Ovarian Neoplasms (3)  ·  Fallopian Tube Neoplasms (2)  ·  Carcinoma, Ovarian Epithelial (1)

Sponsors

EGEN, Inc. (2)  ·  Gynecologic Oncology Group (1)  ·  Imunon (1)

Countries

United States (4)

Top investigators

Premal H Thaker (1)  ·  Premal Thaker, M.D. (1)  ·  Ronald Alvarez, MD (1)  ·  Ronald D. Alvarez, MD (1)

Results publications

PMID 34210826, PMID 36608308

NIH funding

U10CA027469 (1), U10CA180868 (1)